-
A, A'
Antibody staining against GFP without permeabilisation can detect Vkg‐GFP.
-
B, C
Nidogen staining in muscles of animals where mCherry
RNAi
or shi
TS
was expressed in the fat body via CG‐GAL4.
-
D
Quantification of muscle nidogen staining in (B, C). mCherry
RNAi
(n = 23), shi
TS
(n = 24).
-
E, F
Muscle fillets stained with phalloidin (Actin) from animals where mCherry
RNAi
or shi
TS
was expressed in the fat body via CG‐GAL4.
-
G
Quantification of normalised muscle detachment in (E, F). mCherry
RNAi
(n = 8), shi
TS
(n = 9).
-
H, I
Muscle fillets stained with phalloidin (Actin) from QRas
V12
scrib
RNAi
tumour‐bearing animals, where mCherry
RNAi
or UAS‐VkgGFP;UAS‐Cg25C‐GFP was expressed in the fat body (r4‐GAL4). Day 6 muscles used here.
-
J
Quantification of normalised muscle detachment in (H, I). w
1118
(n = 4), QRas
V12
scrib
RNAi
;r4>mCherry
RNAi
(n = 9), QRas
V12
scrib
RNAi
;r4>UAS‐VkgGFP;UAS‐Cg25C‐GFP (n = 6).
-
K, L
Fat body staining for Rab10 in w
1118
and QRas
V12
scrib
RNAi
tumour‐bearing animals.
-
M
Quantification of normalised Rab10 levels in (K, L). w
1118
(n = 15), QRas
V12
scrib
RNAi
(n = 14).
-
N, O
Fat body staining for SPARC in w
1118
and QRas
V12
scrib
RNAi
tumour‐bearing animals.
-
P
Quantification of normalised SPARC levels in (N, O). w
1118
(n = 12), QRas
V12
scrib
RNAi
(n = 13).